Breaking News Instant updates and real-time market news.

BBIO

BridgeBio

$28.26

0.55 (1.98%)

, EIDX

Eidos Therapeutics

$46.58

1.33 (2.94%)

13:03
11/17/19
11/17
13:03
11/17/19
13:03

BridgeBio, Eidos present 'positive' data from Phase 2 clinical trial of AG10

BridgeBio Pharma (BBIO) and Eidos Therapeutics (EIDX) presented positive data from the companies' ongoing Open Label Extension of the Phase 2 clinical trial studying AG10 in patients with symptomatic transthyretin amyloidosis cardiomyopathy. ATTR-CM is a progressive and fatal disease that is an under recognized cause of heart failure. The data were presented in a late-breaking featured science oral presentation at the American Heart Association, or AHA, Scientific Sessions in Philadelphia, Pennsylvania. "This update from our Phase 2 OLE demonstrated continued tolerability of AG10 in patients with advanced ATTR-CM. We also observed meaningfully lower rates of mortality and cardiovascular hospitalizations than what would be expected for untreated ATTR-CM patients with similar disease severity," said Jonathan Fox, Chief Medical Officer of Eidos. "These encouraging data continue to support the development of AG10 as a potentially best-in-class treatment for ATTR-CM patients."

BBIO

BridgeBio

$28.26

0.55 (1.98%)

EIDX

Eidos Therapeutics

$46.58

1.33 (2.94%)

  • 18

    Nov

  • 21

    Nov

BBIO BridgeBio
$28.26

0.55 (1.98%)

07/26/19
RAJA
07/26/19
INITIATION
Target $36
RAJA
Outperform
Raymond James starts BridgeBio at Outperform with $36 price target
As previously reported, Raymond James analyst Dane Leone initiated BridgeBio with an Outperform rating and $36 price target. His Outperform rating is mostly predicated upon the company's key programs for TTR amyloidosis, cholangiocarcinoma and urothelial carcinoma and achondroplasia, Leone stated, adding that the company is unique in the way its project management team incentive compensation is aligned with the outcomes of the specific drugs they are working on.
07/26/19
07/26/19
INITIATION

Fly Intel: Top five analyst initiations
Catch up on today's top five analyst initiations with this list compiled by The Fly: 1. Dentsply Sirona (XRAY) initiated with an In Line at Evercore ISI. 2. BridgeBio (BBIO) initiated with an Outperform at Raymond James. 3. Crispr Therapeutics (CRSP) initiated with a Buy at Canaccord. 4. GeoPark (GPRK) initiated with a Buy at GMP Securities. 5. Neon Therapeutics (NTGN), Gritstone Oncology (GRTS), and Cue Biopharma (CUE) initiated with an Outperform at Baird. This list is just a portion of The Fly's analyst coverage. To see The Fly's full Street Research coverage, click here.
09/13/19
BTIG
09/13/19
NO CHANGE
Target $56
BTIG
Buy
Eidos Therapeutics price target raised to $56 from $38 at BTIG
BTIG analyst Thomas Shrader raised his price target on Eidos Therapeutics (EIDX) to $56 and kept his Buy rating after the decision by its board to reject an acquisition offer from parent company BridgeBio (BBIO) to buy all of its outstanding stock. The analyst notes that he always believed the combined entity would not be a more attractive investment, saying he is positive on the company's "declaration of independence". Shrader further cites the added revenue contribution expected from Eidos Therapeutics' deal with Alexion (ALXN) to develop and commercialize AG10 in Japan.
10/18/19
PIPR
10/18/19
NO CHANGE
Target $50
PIPR
Overweight
BridgeBio has 'best-in-class' potential in achondroplasia, says Piper Jaffray
Piper Jaffray analyst Tyler Van Buren reiterates an Overweight rating on BridgeBio with a $50 price target after new preclinical data for infigratinib in achondroplasia were presented. The drug is effective at lower and less frequent dosing regimens than previously tested, says the analyst, who believes infigratinib could capture 50% achondroplasia market share by 2035, which could amount to over $1.5B in sales. He sees "best-in-class potential" for the drug.
EIDX Eidos Therapeutics
$46.58

1.33 (2.94%)

10/31/19
PIPR
10/31/19
NO CHANGE
Target $55
PIPR
Overweight
Eidos Therapeutics can capture significant market share, says Piper Jaffray
Piper Jaffray analyst Tyler Van Buren keeps his Overweight rating and $55 price target on Eidos Therapeutics, saying its AG10 has the potential capture a 'significant share' of the multi-billion dollar ATTR-cardiomyopathy market. The analyst notes that the company's upcoming PhaseII OLE data at AHA next month could further de-risk the ongoing Phase III program, and upon approval, AG10 may surpass $2.5B in global sales by 2030.
11/01/19
LEHM
11/01/19
DOWNGRADE
Target $45
LEHM
Equal Weight
Eidos Therapeutics downgraded to Equal Weight from Overweight at Barclays
Barclays analyst Gena Wang downgraded Eidos Therapeutics to Equal Weight from Overweight with a $45 price target.
11/01/19
LEHM
11/01/19
DOWNGRADE
Target $45
LEHM
Equal Weight
Barclays downgrades Eidos Therapeutics on valuation after recent run
Barclays analyst Gena Wang downgraded Eidos Therapeutics to Equal Weight from Overweight with a price target of $45, up from $37. While the analyst believes a "meaningful commercial opportunity" exists for AG-10 given the large ATTR-CM market, she sees limited upside after the stock's recent run. Further, there's a lack of meaningful catalysts for Eidos until the Phase 3 topline data from Part A in 2021, Wang tells investors in a research note.
11/01/19
ROTH
11/01/19
NO CHANGE
Target $57
ROTH
Buy
Eidos Therapeutics price target raised to $57 from $51 at Roth Capital
Roth Capital analyst Yasmeen Rahimi raised her price target for Eidos Therapeutics to $57 from $51 and keeps a Buy rating on the shares. Yesterday's Q3 earnings report was "plain vanilla," with ATTRibute-CM enrollment continuing and plans to initiate a Ph3 ATTR-PN study in Q1, Rahimi tells investors in a post-earnings research note. The analyst maintains her "strong conviction" in AG10 as a best-in-class transthyretin stabilizer.

TODAY'S FREE FLY STORIES

MA

MasterCard

$290.37

0.43 (0.15%)

08:56
12/09/19
12/09
08:56
12/09/19
08:56
Conference/Events
MasterCard management to meet with SunTrust »

Field Trip to Company…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 10

    Dec

TTWO

Take-Two

$123.76

-0.14 (-0.11%)

08:56
12/09/19
12/09
08:56
12/09/19
08:56
Conference/Events
Take-Two management to meet with MKM Partners »

Meeting to be held in New…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 13

    Dec

  • 13

    Dec

AAPL

Apple

$270.71

5.15 (1.94%)

, BAC

Bank of America

$33.67

0.57 (1.72%)

08:55
12/09/19
12/09
08:55
12/09/19
08:55
Options
Notable open interest changes for December 9th »

Friday's total…

AAPL

Apple

$270.71

5.15 (1.94%)

BAC

Bank of America

$33.67

0.57 (1.72%)

BMY

Bristol-Myers

$59.94

0.435 (0.73%)

DHR

Danaher

$148.17

1.1 (0.75%)

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 09

    Dec

  • 11

    Dec

  • 15

    Jan

  • 26

    Feb

FNMA

Fannie Mae

$0.00

(0.00%)

, FMCC

Freddie Mac

$0.00

(0.00%)

08:54
12/09/19
12/09
08:54
12/09/19
08:54
Recommendations
Fannie Mae, Freddie Mac analyst commentary  »

Odeon says ruling seems…

FNMA

Fannie Mae

$0.00

(0.00%)

FMCC

Freddie Mac

$0.00

(0.00%)

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

LPSN

LivePerson

$37.81

-0.62 (-1.61%)

08:54
12/09/19
12/09
08:54
12/09/19
08:54
Conference/Events
LivePerson management to meet with Benchmark »

Meeting to be held in San…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 10

    Dec

NNBR

NN, Inc.

$8.00

0.1 (1.27%)

08:53
12/09/19
12/09
08:53
12/09/19
08:53
Recommendations
NN, Inc. analyst commentary  »

NN, Inc. preferred…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

08:52
12/09/19
12/09
08:52
12/09/19
08:52
Conference/Events
Jefferies European economist to hold an analyst/industry conference call »

European Economist Owen,…

LEA

Lear

$124.81

4.05 (3.35%)

08:51
12/09/19
12/09
08:51
12/09/19
08:51
Conference/Events
Lear management to meet with UBS »

Meetings to be held in…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 10

    Dec

  • 11

    Dec

WWD

Woodward

$122.27

2.55 (2.13%)

08:49
12/09/19
12/09
08:49
12/09/19
08:49
Recommendations
Woodward analyst commentary  »

Woodward…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

JKS

JinkoSolar

$20.32

0.56 (2.83%)

08:49
12/09/19
12/09
08:49
12/09/19
08:49
Conference/Events
JinkoSolar management to meet with Roth Capital »

Meeting to be held in San…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 10

    Dec

ABEO

Abeona Therapeutics

$3.00

0.25 (9.09%)

08:46
12/09/19
12/09
08:46
12/09/19
08:46
Hot Stocks
Abeona Therapeutics cleared to initiate EB-101 Phase 3 clinical trial »

Abeona Therapeutics…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

JEC

Jacobs Engineering

$85.02

-0.56 (-0.65%)

08:46
12/09/19
12/09
08:46
12/09/19
08:46
Conference/Events
Jacobs Engineering management to meet with Seaport Global »

Meeting to be held in New…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 10

    Dec

DK

Delek US

$34.30

0.99 (2.97%)

, MPC

Marathon Petroleum

$60.17

0.4 (0.67%)

08:46
12/09/19
12/09
08:46
12/09/19
08:46
Downgrade
Delek US, Marathon Petroleum rating change  »

JPMorgan downgrades Delek…

DK

Delek US

$34.30

0.99 (2.97%)

MPC

Marathon Petroleum

$60.17

0.4 (0.67%)

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

BZUN

Baozun

$35.29

-0.06 (-0.17%)

, AIMT

Aimmune

$29.67

0.51 (1.75%)

08:45
12/09/19
12/09
08:45
12/09/19
08:45
Options
Largest borrow rate increases among liquid names »

Latest data shows the…

BZUN

Baozun

$35.29

-0.06 (-0.17%)

AIMT

Aimmune

$29.67

0.51 (1.75%)

MED

Medifast

$90.67

0.48 (0.53%)

CGC

Canopy Growth

$18.65

0.07 (0.38%)

UVXY

ProShares Trust Ultra VIX Short Term Futures ETF

$15.11

-0.8 (-5.03%)

SCO

Scor ADR

$13.14

-0.3 (-2.23%)

BRFS

BRF S.A.

$8.87

0.22 (2.54%)

ET

Energy Transfer LP

$11.50

-0.1 (-0.86%)

RVLV

Revolve Group

$16.74

-0.46 (-2.67%)

DO

Diamond Offshore

$6.01

0.44 (7.90%)

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 11

    Dec

INFN

Infinera

$6.12

0.115 (1.92%)

08:44
12/09/19
12/09
08:44
12/09/19
08:44
Conference/Events
Infinera management to meet with B. Riley FBR »

Meeting to be held in San…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 09

    Dec

  • 10

    Dec

DPLO

Diplomat Pharmacy

$5.82

0.22 (3.93%)

08:43
12/09/19
12/09
08:43
12/09/19
08:43
Downgrade
Diplomat Pharmacy rating change  »

Diplomat Pharmacy…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

IHRT

iHeartMedia

$14.59

-0.24 (-1.62%)

08:42
12/09/19
12/09
08:42
12/09/19
08:42
Conference/Events
iHeartMedia management to meet with Wolfe Research »

Meeting to be held in New…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 10

    Dec

IDA

Idacorp

$104.61

-0.03 (-0.03%)

08:40
12/09/19
12/09
08:40
12/09/19
08:40
Conference/Events
Idacorp management to meet with Mizuho »

Meeting to be held in New…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 10

    Dec

  • 11

    Dec

ATVI

Activision Blizzard

$55.21

0.22 (0.40%)

08:39
12/09/19
12/09
08:39
12/09/19
08:39
Recommendations
Activision Blizzard analyst commentary  »

Activision Blizzard price…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 13

    Dec

SNY

Sanofi

$46.05

-0.04 (-0.09%)

08:38
12/09/19
12/09
08:38
12/09/19
08:38
Hot Stocks
Sanofi vaccines unit enters agreement with HHS to increase production capability »

Sanofi Pasteur, the…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 09

    Dec

  • 09

    Dec

RFIL

RF Industries

$5.82

0.07 (1.22%)

08:38
12/09/19
12/09
08:38
12/09/19
08:38
Hot Stocks
RF Industries appoints Ray Bibisi as Chief Revenue Officer »

RF Industries announced…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

JJSF

J & J Snack Foods

$188.98

0.94 (0.50%)

08:37
12/09/19
12/09
08:37
12/09/19
08:37
Downgrade
J & J Snack Foods rating change  »

J & J Snack Foods…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

HPE

HP Enterprise

$15.91

-0.02 (-0.13%)

08:37
12/09/19
12/09
08:37
12/09/19
08:37
Conference/Events
HP Enterprise management to meet with Loop Capital »

Dinner Meeting with…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 09

    Dec

  • 09

    Dec

  • 10

    Dec

  • 10

    Dec

ATR

AptarGroup

$112.05

-0.015 (-0.01%)

08:36
12/09/19
12/09
08:36
12/09/19
08:36
Hot Stocks
AptarGroup Unidose Liquid System approved by FDA »

AptarGroup announced that…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

PTON

Peloton

$32.56

1.24 (3.96%)

08:35
12/09/19
12/09
08:35
12/09/19
08:35
Recommendations
Peloton analyst commentary  »

Peloton remains positoned…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 09

    Dec

Get Full Fly Access

Breaking market intelligence sent straight to you
Our team of experts analyze every news story and filter out the noise to deliver real-time market moving news.
Up-to-date information on important industry events
Get real-time updates on events that are moving the market—from conferences and calls to syndicate announcements.
News focused on the companies in your portfolio
Create up to 12 portfolios with 150 stocks each, and see how active they are in market news.